Skip to search formSkip to main contentSkip to account menu

RFS 2000

Known as: RFS-2000, RFS2000 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

rubitecan

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancer.
2004
2004
RFS2000 (9-nitrocamptothecin) in advanced small cell lung cancer, a phase II study of the EORTC New Drug Development Group.
2004
2004
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors
Objective: To investigate the antitumor activity and the safety of RFS2000, an oral topoisomerase I inhibitor, in patients with… 
Review
2004
Review
2004
Rubitecan: 9-NC, 9-Nitro-20(S)-camptothecin, 9-nitro-camptothecin, 9-nitrocamptothecin, RFS 2000, RFS2000.
Rubitecan [Orathecin, 9-nitrocamptothecin, 9NC, RFS 2000] is a topoisomerase I inhibitor extracted from the bark and leaves of… 
2002
2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme.
2002
2002
Radiation enhancement by the combined use of topoisomerase I inhibitors, RFS-2000 or CPT-11, and topoisomerase II inhibitor etoposide in human lung cancer cells.
2000
2000
Preclinical evaluation of the orally active camptothecin analog, RFS-2000 (9-nitro-20(S)-camptothecin) as a radiation enhancer.
Review
1999
Review
1999
Topoisomerase I inhibitors in the treatment of colorectal cancer.
Over the past 10 years, a number of topoisomerase I inhibitors have entered into clinical trials and several of these have been… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)